AITHM James Cook University


Back to listings

On Twitter

Latest tweets

Download Our
Annual Report

07 November 2017

Contact Us

Professor Damon Eisen

PH: (07) 4781 3892



Trial phase

Why is this study important?

Urinary Tract Infections (UTIs) are the most common bacterial infections. They can range from mild infections to life-threatening cases. Recurrent UTIs are also common, particularly in post-menopausal women, and require frequent antibiotic prescriptions. In the long term, this can encourage antibiotic resistance.

The aim of this trial is to assess whether Aspirin in low doses can reduce the frequency of recurrent UTIs in post-menopausal women. If successful, this will benefit many patients as Aspirin is cheaper, more accessible and could result in less dependence on antibiotics, therefore reducing antibiotic resistance.


What will I be asked to do? 

The duration of this trial will be a minimum period of 1 year for each participant. Participants will be randomly allocated to take either 300mg Aspirin or a placebo. These tablets will be taken at night along with one Ural sachet consisting of sodium bicarbonate for 6 months. Following this, patients will cross-over to take either placebo or Aspirin treatment for a further 6 months.

 What are the benefits of taking part in the study?

We cannot guarantee or promise that you will receive any benefit from this research. However, potential benefits can include reduced UTI symptoms, focused medical advice by a healthcare professional and assisting in the advancement of medical research.

 What are the possible risks of taking part?

Possible risks of participating in this study can include:

  • Low risk of bleeding due to aspirin
  • Allergy to aspirin

Who can participate?

Participants are required to be post-menopausal women who have experienced more than three UTIs in a 12-month period.

What about confidentiality?

This study has been reviewed and approved by the Human Research Ethics Committee at James Cook University. All information collected will be treated confidentially and will be used for health research only. No information will be released in a way that would allow an individual to be identified.


Complaints can be made in a confidential manner to any member of the study team, or by directly contacting the:

Ethics Officer

Human Research Ethics Committee

James Cook University

Phone: (07) 4781 5011


How can I participate in the study?

If you’d like to be involved in the trial, please contact Damon Eisen on (07) 4781 3892 or email

The team:

  • Professor Damon Eisen